Abstract: The invention relates to a dermal therapeutic system having a cover layer, an adhesive matrix having a content of, as active ingredient, 2-(3-benzophenyl)propionic acid or [o-(2,6-dichloroanilino)phenyl]acetic acid or a derivative thereof customary in pharmacy, and a removable protective layer, characterised in that the adhesive matrix is an acrylate copolymer adhesive matrix.

Abstract: The invention relates to a transdermal, therapeutic system comprising a coating layer and an adhesive matrix having a fentanyl content.

Abstract: A controlled release ketoprofen patch for the topical application of ketoprofen is described, in addition to methods of treating inflammatory disorders and pain disorders by the administration of the controlled release ketoprofen patch.

Abstract: A controlled release ketoprofen patch for the topical application of ketoprofen is described, in addition to methods of treating inflammatory disorders and pain disorders by the administration of the controlled release ketoprofen patch.

Abstract: Label for the outerwear for thinning of airway secretions.

Abstract: The invention relates to a coloured plaster cover that can be used, e.g., with children, in the case of irritations (formications, burns and itches) resulting from contact with stinging nettles or similar irritations.

Abstract: The invention relates to a dermal therapeutic system having a cover layer, an adhesive matrix having a content of, as active ingredient, 2-(3-benzophenyl)propionic acid or [o-(2,6-dichloroanilino)phenyl]acetic acid or a derivative thereof customary in pharmacy, and a removable protective layer, characterised in that the adhesive matrix is an acrylate copolymer adhesive matrix.

Abstract: The invention is represented by a transdermal medicated patch for the extended release of 17.beta.-estradiol to the skin. The transdermal patch is formed by an outer covering, a matrix containing from 1% to 5% (w/w) 17.beta.-estradiol, and a protective liner which is removed before use. The matrix is formed of pressure-sensitive adhesive acrylic copolymers, in which the active ingredient is dissolved or dispersed. The acrylic copolymers are obtained by radical copolymerization of 2-ethylhexyl acrylate, methyl acrylate, acrylic acid, vinyl acetate, hydroxyethyl acrylate or a mixture thereof. Optionally quantities of less than 0.5% (w/w) of other substances may be added.

Abstract: The invention concerns a transdermal patch for the release through the skin of estradiol and a progestogen agent and a process for its production.

Abstract: The invention relates to a plaster for the treatment of nail mycoses, which s characterized by an antimycotically active substance, clotrimazole and bifonazole being excluded.

Abstract: Transdermal therapeutic systems containing as active ingredients oestradiol and norethisterone acetate have added thereto octyldodecanol to reduce or avert crystal formation after storage. The use of octyldodecanol thus makes it possible to produce a storage-stable system with the active ingredients oestradiol and norethisterone acetate with a high thermodynamic activity.

Abstract: The present invention relates to active substance plasters for the controlled release of active substances to the skin consisting of a backing layer, an adhesive film connected therewith which film is water-soluble and consists of pressure-sensitive adhesive which comprises water-swellable polymers and in which the active substance is at least partially soluble, and of a removable protective layer covering the adhesive film, in which plasters the pressure-sensitive adhesive is based on homo and/or copolymers with at least one derivative of the acrylic or methacrylic acid, and which comprise as active substances, partially or completely dissolved in the adhesive, at a concentration of 0.5 to 10.0%-wt estrogens and their pharmaceutically acceptable derivatives alone or in combination with gestagens.

Abstract: The present invention is related to a new process for selectively preparing isosorbide-5-nitrate (1.4-3.6-dianhydrosorbitol-5-nitrate) by subjecting isomannide (1.4-3.

Abstract: A pharmaceutical preparation comprising:(a) isosorbide dinitrate as active ingredient(b) a solvent for isosorbide dinitrate(c) an ointment consistency agent(d) an emulsifying agent(e) water, and(f) possibly customary preservatives, antioxidants, buffers and/or odorants;where the weight ratio of water: consistency agent including emulsifying agent: solvent is 30 to 80: 3 to 35: 3 to 35, the amount of emulsifying agent is from 0% to 15% by weight and the amount of isosorbide dinitrate is from 2% to 20% by weight. The preparation has an ointment-like consistency and is administered topically to the skin, where it has a high adsorption rate and a long duration of response.

Abstract: Supersaturated aqueous to organic solvent solution of isosorbide dinitrate, process of preparation at elevated temperatures, and use of the supersaturated solutions for the production of infusion solutions.